A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
BeOne Medicines
Genmab
Actuate Therapeutics Inc.
Akeso
Inhibrx Biosciences, Inc
Innovent Biologics (Suzhou) Co. Ltd.
Nelum Corp
Merck Sharp & Dohme LLC